(NASDAQ: ETNB) 89bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
89bio's revenue in 2024 is $0.On average, 4 Wall Street analysts forecast ETNB's revenue for 2026 to be $3,022,553,187, with the lowest ETNB revenue forecast at $744,766,865, and the highest ETNB revenue forecast at $4,703,738,944. On average, 4 Wall Street analysts forecast ETNB's revenue for 2027 to be $20,135,465,799, with the lowest ETNB revenue forecast at $6,187,369,634, and the highest ETNB revenue forecast at $39,284,730,401.
In 2028, ETNB is forecast to generate $57,687,949,147 in revenue, with the lowest revenue forecast at $19,270,473,688 and the highest revenue forecast at $100,361,516,360.